Carol Schafer
Director/Board Member chez REPARE THERAPEUTICS INC.
Fortune : 505 944 $ au 31/03/2024
Profil
Carol Anne Schafer is currently an Independent Director at Insmed, Inc., Director at Immunome, Inc., Independent Director at Kura Oncology, Inc., Independent Director at Repare Therapeutics, Inc., Director at Onegoal New York, and Managing Partner at Hyphen Advisors LLC.
Her former positions include Vice Chairman-Equity Capital Markets at Wells Fargo Securities LLC, Independent Director at Idera Pharmaceuticals, Inc., Independent Director at Five Prime Therapeutics, Inc., VP-Finance, Business Development & Communications at Lexicon Pharmaceuticals, Inc., and MD, VP & Head-Equity Capital Markets at J.P.
Morgan & Co., Inc. (Old).
She received her undergraduate degree from Boston College and her MBA from The Leonard N Stern School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INSMED INCORPORATED
0,01% | 11/05/2023 | 17 260 ( 0,01% ) | 468 264 $ | 31/03/2024 |
REPARE THERAPEUTICS INC.
0,02% | 08/06/2023 | 8 000 ( 0,02% ) | 37 680 $ | 31/03/2024 |
IMMUNOME, INC.
-.--% | 02/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
KURA ONCOLOGY, INC.
-.--% | 31/05/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Carol Schafer
| Sociétés | Poste | Début |
|---|---|---|
| REPARE THERAPEUTICS INC. | Director/Board Member | 01/03/2019 |
| INSMED INCORPORATED | Director/Board Member | 01/04/2020 |
| KURA ONCOLOGY, INC. | Director/Board Member | 03/06/2021 |
| IMMUNOME, INC. | Director/Board Member | 02/01/2024 |
| Hyphen Advisors LLC | Chief Executive Officer | 01/01/2018 |
Onegoal New York
 Onegoal New York Miscellaneous Commercial ServicesCommercial Services Onegoal New York operates a social services organization. The private company is based in New York. | Director/Board Member | 01/03/2019 |
Anciens postes connus de Carol Schafer
| Sociétés | Poste | Fin |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Director/Board Member | 28/09/2022 |
| FIVE PRIME THERAPEUTICS, INC. | Director/Board Member | 16/04/2021 |
Wells Fargo Securities LLC
 Wells Fargo Securities LLC Investment Banks/BrokersFinance Wells Fargo Securities LLC (WFS) is the broker/dealer subsidiary of EVEREN Capital Corp., ultimately owned by Wells Fargo & Co. (NYSE: WFC). Headquartered in New York, WFS delivers a comprehensive suite of banking, capital markets and advisory solutions, such as a full complement of sales, trading and research capabilities, to corporate, government and institutional clients. | Corporate Officer/Principal | 01/09/2018 |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░ ░░░░░ ░░░░ ░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Carol Schafer
| Boston College | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| INSMED INCORPORATED | Health Technology |
| IMMUNOME, INC. | Health Technology |
| KURA ONCOLOGY, INC. | Health Technology |
| REPARE THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
| J.P. Morgan & Co., Inc. (Old) | Finance |
Wells Fargo Securities LLC
Wells Fargo Securities LLC Investment Banks/BrokersFinance Wells Fargo Securities LLC (WFS) is the broker/dealer subsidiary of EVEREN Capital Corp., ultimately owned by Wells Fargo & Co. (NYSE: WFC). Headquartered in New York, WFS delivers a comprehensive suite of banking, capital markets and advisory solutions, such as a full complement of sales, trading and research capabilities, to corporate, government and institutional clients. | Finance |
Onegoal New York
Onegoal New York Miscellaneous Commercial ServicesCommercial Services Onegoal New York operates a social services organization. The private company is based in New York. | Commercial Services |
| Hyphen Advisors LLC |
